# A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

> **NCT00275262** · PHASE2 · TERMINATED · sponsor: **Abbott** · enrollment: 25 (actual)

## Conditions studied

- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- **DRUG:** Matched placebo

## Key facts

- **NCT ID:** NCT00275262
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2010-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275262, "A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00275262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*